Posted inHematology-Oncology news
Efficacy and Safety of All-Oral Ixazomib, Pomalidomide, and Dexamethasone in Triple-Class Exposed Multiple Myeloma: Insights from a Phase II Study
This phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-risk cohort.